Format

Send to

Choose Destination
Surg Oncol Clin N Am. 2017 Jan;26(1):17-31. doi: 10.1016/j.soc.2016.07.010.

Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.

Author information

1
Division of Hematology/Oncology, Department of Medicine, Zuckerberg San Francisco General Hospital, 995 Potrero Avenue, Building 80, 4th Floor, San Francisco, CA 94110, USA.
2
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USA.
3
Division of Infectious Diseases, Department of Medicine, University of California at San Francisco, 513 Parnassus Avenue, Medical Science Room 420E, Box 0654, San Francisco, CA 94143, USA. Electronic address: joel.palefsky@ucsf.edu.

Abstract

Anal cancer is an increasingly common non-AIDS-defining cancer among individuals infected with the human immunodeficiency virus (HIV). It is associated with human papillomavirus (HPV). HPV16 is the most common genotype detected in anal cancers. The HPV types detected in anal cancer are included in the 9-valent vaccine. HPV vaccines have demonstrated efficacy in reducing anal precancerous lesions in HIV-infected individuals. Standard treatment has been fluorouracil and mitomycin (or cisplatin) plus radiation. Continued studies are needed to test new treatment strategies in HIV-infected patients with anal cancer to determine which treatment protocols provide the best therapeutic index.

KEYWORDS:

Anal cancer; HIV; HPV; HPV vaccination; Immunosuppression

PMID:
27889034
PMCID:
PMC5331942
DOI:
10.1016/j.soc.2016.07.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center